The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly and Company. The funding will support IDRI's continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB). According to the World Health Organization, there were nearly 9 million new cases of TB in 2010, close to half a million of which were resistant to drugs that once effectively treated the disease...
More...
More...